`
`SITC Smalley Award 2013 Recipient - Society for Immunotherapy of Cancer (SITC)
`
`
`
`SUBSCRIBE
`
`SIGN IN
`
`SITC Smalley Award 2013
`Recipient
`
`Keyword Search...
`
`
`
`MAKE A GIFT
`
`Carl H. June, MD
`University of Pennsylvania
`
`Return to ...
`
`Richard V. Smalley,
`MD Memorial Award
`and Lectureship
`SITC Awards
`homepage
`
`Carl June is the Richard W.
`Vague Professor in
`Immunotherapy in the
`Department of Pathology and
`Laboratory Medicine. He is
`currently Director of Translational
`Research at the Abramson
`Cancer Center at the University
`of Pennsylvania, and is an
`Investigator of the Abramson
`Family Cancer Research Institute. He is a graduate of the Naval
`Academy in Annapolis, and Baylor College of Medicine in
`Houston, 1979. He had graduate training in Immunology and
`malaria with Dr. Paul-Henri Lambert at the World Health
`Organization, Geneva, Switzerland from 1978-79, and post-
`doctoral training in transplantation biology with Dr. E. Donnell
`Thomas and Dr. John Hansen at the Fred Hutchinson Cancer
`Research Center in Seattle from 1983 - 1986. He is board
`certified in Internal Medicine and Medical Oncology. He founded
`the Immune Cell Biology Program and was head of the
`Department of Immunology at the Naval Medical Research
`
`https://www.sitcancer.org/funding/named-funds-and-awards2/smalley/2013
`
`1/2
`
`UPenn Ex. 2045
`Miltenyi v. UPenn
`IPR2022-00853
`
`
`
`7/19/22, 10:49 AM
`
`SITC Smalley Award 2013 Recipient - Society for Immunotherapy of Cancer (SITC)
`
`Institute from 1990 to 1995 before joining the faculty of the
`Perelman School of Medicine in 1999. He maintains a research
`laboratory that studies various mechanisms of lymphocyte
`activation that relate to immune tolerance and adoptive
`immunotherapy for cancer and chronic infection.
`Research Overview
`To apply principles of the cellular immune system to develop
`novel therapies for cancer and chronic infection. We focus on the
`human immune system and study the biology of lymphocytes in
`order to manipulate their function and development, and then
`apply this knowledge for potential new avenues of
`immunotherapy. For several years we have been interested in
`the notion that various costimulatory molecules might have a role
`in specifying the fate of various lymphocyte subsets. Current
`projects are studying the role of CD28 and TNF family members
`in lymphocyte function and proliferation. Other projects involve
`developing advanced technology to engineer lymphocytes
`subsets for enhanced therapeutic effector functions. A variety of
`in vitro assays and humanized mouse models are used to
`discover new approaches and test for potential therapeutic
`activity.
`
`(Biography as of 2013)
`
`
`
`
`
`
`
`MEMBERSHIP
`LINKS
`
`GET
`INVOLVED
`
`Join
`
`Renew
`
`Email Sign-up
`
`Volunteer
`
`Member Directory
`
`Support SITC
`
`My Profile
`
`Contact Us
`
`© 2022 Society for Immunotherapy of Cancer (SITC). All rights reserved. Privacy Policy.
`Tel: +1 414 271 2456 | Fax: +1 414 276 3349 |
`555 East Wells Street, Suite 1100 | Milwaukee,
`WI | 53202-3823 | USA
`Email: info@sitcancer.org
`
`https://www.sitcancer.org/funding/named-funds-and-awards2/smalley/2013
`
`2/2
`
`UPenn Ex. 2045
`Miltenyi v. UPenn
`IPR2022-00853
`
`